RESUMO
Extra-axial chordoma is a rare neoplasm of extra-axial skeleton and soft tissue that shares identical histomorphologic and immunophenotypic features with midline chordoma. While genetic changes in conventional chordoma have been well-studied, the genomic alterations of extra-axial chordoma have not been reported. It is well known that conventional chordoma is a tumor with predominantly non-random copy number alterations and low mutational burden. Herein we describe the clinicopathologic and genomic characteristics of six cases of extra-axial chordoma, with genome-wide high-resolution single nucleotide polymorphism array, fluorescence in situ hybridization and targeted next-generation sequencing (NGS) analysis. The patients presented at a mean age of 33 years (range: 21-54) with a female to male ratio of 5:1. Four cases were histologically conventional type, presented with bone lesions and three of them had local recurrence. Two cases were poorly differentiated chordomas, presented with intra-articular soft tissue masses and both developed distant metastases. All cases showed brachyury positivity and the two poorly differentiated chordomas showed in addition loss of INI-1 expression by immunohistochemical analysis. Three of four extra-axial conventional chordomas showed simple genome with loss of chromosome 22 or a heterozygous deletion of SMARCB1. Both poorly differentiated chordomas demonstrated a complex hyperdiploid genomic profile with gain of multiple chromosomes and homozygous deletion of SMARCB1. Our findings show that heterozygous deletion of SMARCB1 or the loss of chromosome 22 is a consistent abnormality in extra-axial chordoma and transformation to poorly differentiated chordoma is characterized by homozygous loss of SMARCB1 associated with genomic complexity and instability such as hyperdiploidy.
Assuntos
Biomarcadores Tumorais/genética , Cordoma/genética , Proteínas Fetais/genética , Proteína SMARCB1/genética , Proteínas com Domínio T/genética , Adulto , Cordoma/patologia , Deleção Cromossômica , Cromossomos Humanos Par 22/genética , Feminino , Deleção de Genes , Sequenciamento de Nucleotídeos em Larga Escala , Homozigoto , Humanos , Hibridização in Situ Fluorescente , Masculino , Pessoa de Meia-Idade , Mutação/genética , Polimorfismo de Nucleotídeo Único/genética , Adulto JovemRESUMO
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare subtype of renal cell carcinoma with characteristic histologic features and chromosomal alterations. Although typically indolent, a small subset of cases has been reported to exhibit aggressive clinical behavior. We retrospectively identified 33 patients with MTSCC, consisting of 10 cases of locally advanced/metastatic MTSCC (pT3 or N1 or M1) and 23 kidney-confined MTSCC (pT1/T2) without disease recurrence or progression. Utilizing a single-nucleotide polymorphism array and a targeted next-generation sequencing platform, we examined genome-wide molecular alterations in 24 cases, including 11 available samples from 8 patients with locally advanced/metastatic MTSCC. Ten patients with locally advanced/metastatic MTSCC were 8 females (80%) and 2 males (20%). At nephrectomy, 7 of these 10 cases (70%) were pT3 or pN1 while the remaining 3 (30%) were pT1/T2. Eight patients (80%) developed metastases and common sites included lymph node (4, 40%), bone (4, 40%), and retroperitoneum (3, 30%). Four patients died of disease (40%) during follow-up. Locally advanced/metastatic MTSCCs shared typical MTSCC genomic profiles with loss of chromosomes 1, 4, 6, 8, 9, 13, 14, 15, and 22, while some exhibited additional complex genomic alterations, most frequently a relative gain of 1q (7/8). Homozygous loss of CDKN2A/B was observed in 3 (38%) locally advanced/metastatic MTSCCs. Tumor necrosis, solid nested/sheet pattern, irregular trabecular/single-file infiltration in a desmoplastic stroma, lymphovascular space invasion, and increased mitotic activity were associated with locally advanced/metastatic MTSCCs (all p < 0.05). Our findings reveal that MTSCCs with aggressive clinical behavior have progressed through clonal evolution; CDKN2A/B deletion and additional complex genomic abnormalities may contribute to this process. Recognizing the morphologic presentation of high-grade MTSCC and evaluating adverse histologic features seen in these tumors can help establish a definitive diagnosis and stratify patients for treatment and prognostication.
Assuntos
Adenocarcinoma Mucinoso/genética , Adenocarcinoma Mucinoso/patologia , Inibidor de Quinase Dependente de Ciclina p15/genética , Inibidor p16 de Quinase Dependente de Ciclina/genética , Neoplasias Renais/genética , Neoplasias Renais/patologia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos RetrospectivosRESUMO
Evolution of poorly differentiated chordoma from conventional chordoma has not been previously reported. We encountered a case of a poorly differentiated chordoma with evidence of whole-genome doubling arising from a SMARCB1-deficient conventional chordoma. The tumor presented as a destructive sacral mass in a 43-year-old man and was comprised of a highly cellular poorly differentiated chordoma with small, morphologically distinct nodules of conventional chordoma accounting for <5% of the total tumor volume. Immunohistochemistry (IHC) revealed both components were strongly reactive for brachyury and lacked normal staining for INI1. Single nucleotide polymorphism (SNP) array analysis identified multiple genomic imbalances in the conventional component, including deletions of 1p, 3p, and 22q (involving SMARCB1) and loss of chromosomes 5 and 15, while the poorly differentiated component exhibited the same aberrations at a more profound level with additional loss of chromosome 4, low level focal deletion of 17p (involving TP53), and tetraploidy. Homozygous deletion of SMARCB1 was present in both components. Fluorescence in situ hybridization (FISH) analysis confirmed the relevant deletions in both components as well as genome doubling in the poorly differentiated tumor. This case suggests that SMARCB1 loss is an early event in rare conventional chordomas that could potentially evolve into poorly differentiated chordoma through additional genomic aberrations such as genome doubling. Further studies with additional patients will be needed to determine if genome doubling is a consistent pathway for evolution of poorly differentiated chordoma.
Assuntos
Cordoma/genética , Deleção Cromossômica , Proteína SMARCB1/genética , Neoplasias da Coluna Vertebral/genética , Tetraploidia , Adulto , Cordoma/patologia , Proteínas Fetais/genética , Proteínas Fetais/metabolismo , Humanos , Masculino , Proteína SMARCB1/deficiência , Sacro/patologia , Neoplasias da Coluna Vertebral/patologia , Proteínas com Domínio T/genética , Proteínas com Domínio T/metabolismoRESUMO
In patients with multiple myeloma, plasmablastic transformation in the bone marrow is rare and associated with poor outcomes. The significance of discordant extramedullary plasmablastic transformation in patients with small, mature clonal plasma cells in the bone marrow has not been well studied. Here, we report the clinicopathologic, cytogenetic, and molecular features of 10 such patients (male/female: 6/4, median age: 65 y, range: 48 to 76 y) with an established diagnosis of multiple myeloma in the bone marrow composed of small, mature plasma cells in parallel with a concurrent or subsequent extramedullary plasmablastic transformation. Eight patients with available survival data showed an overall aggressive clinical course with a median survival of 4.5 months after the diagnosis of extramedullary plasmablastic transformation, despite aggressive treatment and even in patients with low-level bone marrow involvement. Pathologically, the extramedullary plasmablastic myeloma were clonally related to the corresponding bone marrow plasma cells, showed high levels of CMYC and/or P53 expression with a high Ki-67 proliferation index by immunohistochemistry and harbored more complex genomic aberrations including frequent mutations in the RAS pathway and MYC rearrangements compared with their bone marrow counterparts. In summary, although genetic and immunohistochemical studies were not uniformly performed on all cases due to the retrospective nature of this study, our data suggest that discordant extramedullary plasmablastic transformation of multiple myeloma has an aggressive clinical course and is characterized by frequent mutations in the RAS pathway and more complex genomic abnormalities.
Assuntos
Mieloma Múltiplo/genética , Mieloma Múltiplo/patologia , Plasmócitos/patologia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
A correction to this paper has been published and can be accessed via a link at the top of the paper.
RESUMO
Recent genomic research efforts in multiple myeloma have revealed clinically relevant molecular subgroups beyond conventional cytogenetic classifications. Implementing these advances in clinical trial design and in routine patient care requires a new generation of molecular diagnostic tools. Here, we present a custom capture next-generation sequencing (NGS) panel designed to identify rearrangements involving the IGH locus, arm level, and focal copy number aberrations, as well as frequently mutated genes in multiple myeloma in a single assay. We sequenced 154 patients with plasma cell disorders and performed a head-to-head comparison with the results from conventional clinical assays, i.e., fluorescent in situ hybridization (FISH) and single-nucleotide polymorphism (SNP) microarray. Our custom capture NGS panel had high sensitivity (>99%) and specificity (>99%) for detection of IGH translocations and relevant chromosomal gains and losses in multiple myeloma. In addition, the assay was able to capture novel genomic markers associated with poor outcome such as bi-allelic events involving TP53. In summary, we show that a multiple myeloma designed custom capture NGS panel can detect IGH translocations and CNAs with very high concordance in relation to FISH and SNP microarrays and importantly captures the most relevant and recurrent somatic mutations in multiple myeloma rendering this approach highly suitable for clinical application in the modern era.
RESUMO
Renal medullary carcinoma is a rare but highly aggressive type of renal cancer occurring in patients with sickle cell trait or rarely with other hemoglobinopathies. Loss of SMARCB1 protein expression, a core subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, has emerged as a key diagnostic feature of these tumors. However, the molecular mechanism underlying this loss remains unclear. We retrospectively identified 20 patients diagnosed with renal medullary carcinoma at two institutions from 1996 to 2017. All patients were confirmed to have sickle cell trait, and all tumors exhibited a loss of SMARCB1 protein expression by immunohistochemistry. The status of SMARCB1 locus was examined by fluorescence in situ hybridization (FISH) using 3-color probes, and somatic alterations were detected by targeted next-generation sequencing platforms. FISH analysis of all 20 cases revealed 11 (55%) with concurrent hemizygous loss and translocation of SMARCB1, 6 (30%) with homozygous loss of SMARCB1, and 3 (15%) without structural or copy number alterations of SMARCB1 despite protein loss. Targeted sequencing revealed a pathogenic somatic mutation of SMARCB1 in one of these 3 cases that were negative by FISH. Tumors in the 3 subsets with different FISH findings largely exhibited similar clinicopathologic features, however, homozygous SMARCB1 deletion was found to show a significant association with the solid growth pattern, whereas tumors dominated by reticular/cribriform growth were enriched for SMARCB1 translocation. Taken together, we demonstrate that different molecular mechanisms underlie the loss of SMARCB1 expression in renal medullary carcinoma. Biallelic inactivation of SMARCB1 occurs in a large majority of cases either via concurrent hemizygous loss and translocation disrupting SMARCB1 or by homozygous loss.
Assuntos
Carcinoma Medular/genética , Neoplasias Renais/genética , Proteína SMARCB1/genética , Proteína SMARCB1/metabolismo , Adolescente , Adulto , Carcinoma Medular/metabolismo , Criança , Feminino , Variação Genética , Humanos , Neoplasias Renais/metabolismo , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
The genetic aberrations that drive mixed phenotype acute leukemia (MPAL) remain largely unknown, with the exception of a small subset of MPALs harboring BCR -ABL1 and MLL translocations. We performed clinicopathologic and genetic evaluation of 52 presumptive MPAL cases at Memorial Sloan Kettering Cancer Center. Only 29 out of 52 (56%) cases were confirmed to be bona fide MPAL according to the 2016 World Heath Organization classification. We identified PHF6 and DNMT3A mutations as the most common recurrent mutations in MPAL, each occurring in 6 out of 26 (23%) cases. These mutations are mutually exclusive of each other and BCR-ABL1/MLL translocations. PHF6- and DNMT3A-mutated MPAL showed marked predilection for T-lineage differentiation (5/6 PHF6 mutated, 6/6 DNMT3A mutated). PHF6-mutated MPAL occurred in a younger patient cohort compared with DNMT3A-mutated cases (median age, 27 years vs 61 years, P < .01). All 3 MPAL cases with both T- and B-lineage differentiation harbored PHF6 mutations. MPAL with T-lineage differentiation was associated with nodal or extramedullary involvement (9/15 [60%] vs 0, P = .001) and a higher relapse incidence (78% vs 22%, P = .017) compared with those without T-lineage differentiation. Sequencing studies on flow-cytometry-sorted populations demonstrated that PHF6 mutations are present in all blast compartments regardless of lineage differentiation with high variant allele frequency, implicating PHF6 as an early mutation in MPAL pathogenesis. In conclusion, PHF6 and DNMT3A mutations are the most common somatic alterations identified in MPAL and appear to define 2 distinct subgroups of MPAL with T-lineage differentiation with inferior outcomes.
Assuntos
Proteínas de Transporte/genética , DNA (Citosina-5-)-Metiltransferases/genética , Leucemia Aguda Bifenotípica/diagnóstico , Linfócitos T/citologia , Doença Aguda , Adolescente , Adulto , Idoso , Diferenciação Celular/genética , Criança , Pré-Escolar , DNA Metiltransferase 3A , Intervalo Livre de Doença , Feminino , Humanos , Lactente , Leucemia Aguda Bifenotípica/genética , Leucemia Aguda Bifenotípica/mortalidade , Masculino , Pessoa de Meia-Idade , Mutação , Proteínas Repressoras , Taxa de SobrevidaAssuntos
Diferenciação Celular , Células Eritroides/patologia , Leucemia Mieloide Aguda/patologia , Megacariócitos/patologia , Mutação , Transdução de Sinais , Proteína Supressora de Tumor p53/genética , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Células Eritroides/metabolismo , MAP Quinases Reguladas por Sinal Extracelular/genética , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Humanos , Janus Quinase 2/genética , Janus Quinase 2/metabolismo , Leucemia Mieloide Aguda/genética , Masculino , Megacariócitos/metabolismo , Pessoa de Meia-Idade , PrognósticoRESUMO
Spitzoid neoplasms are a distinct group of melanocytic tumors. Genetically, they lack mutations in common melanoma-associated oncogenes. Recent studies have shown that spitzoid tumors may contain a variety of kinase fusions, including ROS1, NTRK1, ALK, BRAF, and RET fusions. We report herein the discovery of recurrent NTRK3 gene rearrangements in childhood melanocytic neoplasms with spitzoid and/or atypical features, based on genome-wide copy number analysis by single-nucleotide polymorphism array, which showed intragenic copy number changes in NTRK3. Break-apart fluorescence in situ hybridization confirmed the presence of NTRK3 rearrangement, and a novel MYO5A-NTRK3 transcript, representing an in-frame fusion of MYO5A exon 32 to NTRK3 exon 12, was identified using a rapid amplification of cDNA ends-based anchored multiplex PCR assay followed by next-generation sequencing. The predicted MYO5A-NTRK3 fusion protein consists of several N-terminal coiled-coil protein dimerization motifs encoded by MYO5A and C-terminal tyrosine kinase domain encoded by NTRK3, which is consistent with the prototypical structure of TRK oncogenic fusions. Our study also demonstrates how array-based copy number analysis can be useful in discovering gene fusions associated with unbalanced genomic aberrations flanking the fusion points. Our findings add another potentially targetable kinase fusion to the list of oncogenic fusions in melanocytic tumors.
Assuntos
Fusão Gênica/genética , Melanoma/genética , Receptor trkC/genética , Quinase do Linfoma Anaplásico , Receptor com Domínio Discoidina 2/genética , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Mutação , Cadeias Pesadas de Miosina/genética , Miosina Tipo V/genética , Fusão Oncogênica/genética , Proteínas de Fusão Oncogênica/genética , Proteínas Proto-Oncogênicas B-raf/genética , Proteínas Proto-Oncogênicas c-ret/genética , Receptores Proteína Tirosina Quinases/genética , Análise de Sequência de DNARESUMO
Here, comprehensive analysis was performed on the molecular and clinical features of colorectal carcinoma harboring chromosome 20q amplification. Tumor and normal DNA from patients with advanced colorectal carcinoma underwent next-generation sequencing via MSK-IMPACT, and a subset of case samples was subjected to high-resolution microarray (Oncoscan). Relationships between genomic copy number and transcript expression were assessed with The Cancer Genome Atlas (TCGA) colorectal carcinoma data. Of the colorectal carcinoma patients sequenced (n = 401) with MSK-IMPACT, 148 (37%) had 20q gain, and 30 (7%) had 20q amplification. In both the MSK-IMPACT and TCGA datasets, BCL2L1 was the most frequently amplified 20q oncogene. However, SRC was the only recognized 20q oncogene with a significant inverse relationship between mRNA upregulation and RAS/RAF mutation (OR, -0.4 ± 0.2, P = 0.02). In comparison with 20q diploid colorectal carcinoma, 20q gain/amplification was associated with wild-type KRAS (P < 0.001) and BRAF (P = 0.01), microsatellite stability (P < 0.001), distal primary tumors (P < 0.001), and mutant TP53 (P < 0.001), but not stage. On multivariate analysis, longer overall survival from the date of metastasis was observed with chromosome 20q gain (P = 0.02) or amplification (P = 0.04) compared with diploid 20q.Implications: 20q amplification defines a subset of colorectal cancer patients with better overall survival from the date of metastasis, and further studies are warranted to assess whether the inhibition of 20q oncogenes, such as SRC, may benefit this subset of patients. Mol Cancer Res; 15(6); 708-13. ©2017 AACR.
Assuntos
Cromossomos Humanos Par 20/genética , Neoplasias do Colo/genética , Neoplasias do Colo/mortalidade , Instabilidade de Microssatélites , Anticorpos Monoclonais/uso terapêutico , Cetuximab/uso terapêutico , Neoplasias do Colo/tratamento farmacológico , Neoplasias Colorretais/tratamento farmacológico , Neoplasias Colorretais/genética , Neoplasias Colorretais/mortalidade , Receptores ErbB/antagonistas & inibidores , Humanos , Mutação , Panitumumabe , Modelos de Riscos Proporcionais , Análise de Sobrevida , Quinases raf/genética , Proteínas ras/genéticaRESUMO
OBJECTIVE: This study examined data provided by the US Department of Education's Rehabilitation Services Administration (RSA) in an effort to evaluate the relationship between (a) demographic variables and vocational rehabilitation (VR) services and (b) the employment outcomes of transition-age youth with traumatic brain injuries. SETTING: Not applicable. PARTICIPANTS: Data for 1546 transition-age youth (ie, 16-25 years of age) with traumatic brain injuries were examined. DESIGN: Purposeful selection of multivariate logistic regression was employed to analyze the data. MAIN MEASURES: Not applicable. RESULTS: Receipt of more VR services at higher expenditure levels over shorter periods of time was related to case closure in successful competitive employment status. Also, higher levels of education at the time of enrollment in the VR program (ie, bachelor's degrees or higher); nonreceipt of social security disability benefits at the time of enrollment in the VR program; and receipt of VR services such as occupational/vocational training, job search, job placement, on-the-job support, maintenance, and information/referral were associated with competitive employment outcomes. CONCLUSION: Client demographic and VR service-related variables significantly predict competitive employment outcomes for transition-age youth with traumatic brain injuries. Vocational rehabilitation services should focus on the specific interventions that are most closely associated with successful rehabilitation.
Assuntos
Lesões Encefálicas Traumáticas/reabilitação , Emprego , Reabilitação Vocacional , Adolescente , Adulto , Pessoas com Deficiência , Feminino , Humanos , Modelos Logísticos , Masculino , Adulto JovemRESUMO
The primary purpose of this study was to evaluate the employment outcomes of transition-aged adults with autism spectrum disorders (ASD) served by vocational rehabilitation services (VR) over the last 10 years by state. A secondary purpose was to compare employment outcomes of individuals with ASD to those of the overall transition-aged population served by VR for the same time period. Although there was variability both within and among states, the results of this study indicate that, over time, the number of young adults with ASD seeking VR services has increased; however, employment outcomes including the percent of adults with ASD achieving employment, the number of hours worked, and wages earned have not improved for this group. The cost to provide VR services to transition-aged adults with ASD was relatively stable over time. Transition-aged adults with ASD were more likely to become successfully employed as a result of receiving VR services than the overall population of transition-aged adults served by VR. However, the employed transition-aged adults consistently worked fewer hours and earned lower wages than those in the overall population. Factors that may influence variability within and among states, and between groups, and implications for research and practice are discussed.
Assuntos
Transtornos Globais do Desenvolvimento Infantil/epidemiologia , Transtornos Globais do Desenvolvimento Infantil/reabilitação , Emprego/estatística & dados numéricos , Avaliação de Resultados em Cuidados de Saúde , Reabilitação Vocacional/estatística & dados numéricos , Adolescente , Adulto , Análise Custo-Benefício , Bases de Dados Factuais/estatística & dados numéricos , Feminino , Humanos , Masculino , Prevalência , Reabilitação Vocacional/economia , Salários e Benefícios/estatística & dados numéricos , Estados Unidos/epidemiologia , Adulto JovemRESUMO
This study investigated whether sheltered workshops help prepare individuals with autism spectrum disorder (ASD) for competitive employment within the community. Two groups of individuals were compared: (a) 215 supported employees who were in sheltered workshops prior to entering supported employment and (b) 215 supported employees who were not in sheltered workshops. Individuals from both groups were matched based on their primary diagnosis, secondary diagnosis (if present), and gender. Results showed that there were no differences in rates of employment between these two groups. However, individuals who participated in sheltered workshops earned significantly less (US$129.36 versus US$191.42 per week), and cost significantly more to serve (US$6,065.08 versus US$2,440.60), than their non-sheltered workshop peers. Results presented here suggest that individuals with ASD achieve better vocational outcomes if they do not participate in sheltered workshops prior to enrolling in supported employment.
Assuntos
Transtornos Globais do Desenvolvimento Infantil/terapia , Educação/métodos , Emprego , Adulto , Criança , Transtornos Globais do Desenvolvimento Infantil/psicologia , Transtornos Globais do Desenvolvimento Infantil/reabilitação , Feminino , Humanos , Masculino , Resultado do TratamentoRESUMO
The cost efficiency of supported employees with intellectual disabilities who were served by vocational rehabilitation agencies throughout the United State from 2002 to 2007 was explored. Findings indicate that, on average, supported employees with intellectual disabilities were cost-efficient from the taxpayers' perspective regardless of whether they had secondary disabilities. In addition, no changes in cost efficiency were found during the period investigated. The data, however, did demonstrate considerable variability in cost efficiency throughout the United States and its territories.
Assuntos
Readaptação ao Emprego/economia , Deficiência Intelectual/economia , Deficiência Intelectual/reabilitação , Reabilitação Vocacional/economia , Adulto , Análise Custo-Benefício , Avaliação da Deficiência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estados UnidosRESUMO
This article examines the cost of services and employment outcomes obtained by adults with autism within the United States vocational rehabilitation (VR) system. It found that the number of such individuals has increased by more than 121 percent from 2002 to 2006. Moreover, though adults with autism were employed at higher rates than most disability groups investigated, they tended to work far fewer hours and earn less in wages per week. The study also found that adults with autism were among the most costly individuals to serve.
Assuntos
Transtorno Autístico/economia , Transtorno Autístico/reabilitação , Readaptação ao Emprego/estatística & dados numéricos , Reabilitação Vocacional , Adulto , Fatores Etários , Transtorno Autístico/epidemiologia , Custos e Análise de Custo/estatística & dados numéricos , Pessoas com Deficiência/reabilitação , Pessoas com Deficiência/estatística & dados numéricos , Readaptação ao Emprego/economia , Feminino , Humanos , Masculino , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Reabilitação Vocacional/economia , Salários e Benefícios/estatística & dados numéricos , Resultado do Tratamento , Desemprego/estatística & dados numéricos , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: The purpose of this study was to determine whether supported employees with psychiatric disorders cost Vocational Rehabilitation more to serve than supported employees with other conditions (e.g., mental retardation). METHOD: A structured cost-accounting methodology was used to compare the adjusted costs (in FY 2005 dollars) of services received by all supported employees funded by Vocational Rehabilitation in Wisconsin from FY 2002 to FY 2005. RESULTS: Supported employees with psychotic and non-psychotic disorders were among the least costly populations to serve via supported employment. They averaged annual per capita expenditures of $3,846 and $2,579, respectively. Supported employees, as a whole, generated average annual per capita expenditures of $4,683. CONCLUSIONS: Based upon data presented here and by other researchers, it would appear that individuals with psychiatric disorders are cheaper to serve than populations more traditionally referred to supported employment (e.g., individuals with mental retardation). If this conclusion is disseminated to referring agencies, perhaps individuals with psychiatric disorders will be referred to supported employment in greater numbers.
Assuntos
Readaptação ao Emprego/economia , Readaptação ao Emprego/estatística & dados numéricos , Transtornos Mentais , Reabilitação Vocacional/economia , Reabilitação Vocacional/estatística & dados numéricos , Análise Custo-Benefício , Humanos , Transtornos Mentais/economia , Transtornos Mentais/epidemiologia , Transtornos Mentais/psicologiaRESUMO
This article describes the objectives and methods involved in economic analyses of rehabilitation services. Demonstrated approaches to cost-effectiveness and cost-benefit studies are presented, illustrated with examples from the contemporary literature. The strengths and limitations of economic analyses are considered within the context of current trends in rehabilitation policy and practice.